You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202231 - 202240 of 207726 results
  1. Therapeutic Development of RNAi-based inhibitors against the Hepatitis Delta Viru

    SBC: Somagenics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Hepatitis D virus (HDV) infection is the most severe type of viral hepatitis, often causing accelerated liver damage that leads to end-stage liver disease. About 10-15 million individuals are infected by HDV worldwide.The absence of an effective treatment for acute forms of the disease and the limited efficacy of current treatments for the chronic infection jus ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. XHA-A Novel Tolerance Therapeutic for Allergic Rhinitis

    SBC: VIRTICI LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to extend the development of a novel compound that can reprogram memory T lymphocytes to induce tolerance in allergic rhinitis (AR). AR is one of the most common chronic diseases in the United States (US) and is estimated to affect more than 50 million people [1,2]. As a result, the annual US economic burden of AR exceeds 12 billio ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Identification of novel broad-spectrum Dengue antivirals

    SBC: ARISAN THERAPEUTICS INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Dengue is the most common mosquito-borne viral disease in the world with no approved therapeutic treatment or vaccine to help those exposed to the virus. World Health Organization estimates that 40% of the world's population is at risk from Dengue with approximately 100 million cases annually. For the most part, Dengue is self-limiting albeit with debilita ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Targeted Inactivation of the CCR5 HIV Coreceptor with Peptide Nucleic Acids

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Over 34 million people are currently living with HIV/AIDS. Combination antiviral therapies have significantly reduced the morbidity and mortality of the disease; however, there is currently no cure for the disease. Discovery that a naturally occurring variant of CCR5, the delta32 mutation, renders cells resistant to HIV infection has led to efforts by several a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. N-acetylglucosamine analogs for the treatment of Multiple Sclerosis.

    SBC: GLIXIS THERAPEUTICS, LLC            Topic: NIAID

    Abstract Multiple sclerosis (MS) is a T-cell mediated autoimmune disorder of the central nervous system. Current treatment strategies for MS are predominated by injectable therapies that do not target an underlying cause of the disease, have modest efficacy and have high cost and/or side effects that limit tolerability and compliance. An oral therapy that promotes self-tolerance by targeting an u ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. A rapid, accurate, and easy-to-use diagnostic assay for STIs

    SBC: AI BIOSCIENCES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The aim of this application is to develop a rapid, easy-to-use, and inexpensive multi-sample diagnostic system to identify sexually transmitted infection (STI) pathogens, such as Chlamydia trachomatis (CT) and Neisseriagonorrhoeae (NG) in non-traditional healthcare settings. According to the CDC, chlamydia and gonorrhea, caused by C. trachomatis and N. gonorrho ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A Sensitive and Serotype-Specific Dengue Diagnostic Test for Low-Resource Setting

    SBC: AI BIOSCIENCES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Dengue is transmitted mainly by the Aedes aegypti mosquitoes which inhabit the tropics, making Dengue endemic to these areas. It is caused by four genetically and serologically related viruses, termed DENV1, DENV2, DENV3, and DENV4. Dengue infection is a leading cause of illness and death in the tropics and subtropics, including Puerto Rico and the U.S. Virgin ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. An immunomodulatory yeast-derived beta glucan as a component of a conjugate

    SBC: BIOTHERA            Topic: NIAID

    DESCRIPTION (provided by applicant): Fungal infections, particularly in immunocompromised patients, are a serious and growing problem. Although antifungal therapeutics have improved greatly, failures and relapse are common. Aspergillus fumigatus is a primary cause of these infections in several patient populations: transplants, leukemics, genetic deficiencies such as chronic granulomatous disease ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Therapeutic amyloid fibrils

    SBC: CARDINAL THERAPEUTICS INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Accumulation of amyloid fibrils correlates with neurodegeneration in various brain diseases, but the biological role of the fibrils is unclear. Our previous experiments established that amyloidogenic peptides from thesmall heat shock protein, HspB5, and from Amyloid ? fibrils, characteristic of Alzheimer's disease, were therapeutic when administered syste ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Development, Production and Testing of VLP based Respiratory Syncytial Virus (RSV

    SBC: TECHNOVAX INC            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop a safe and efficacious virus-like particle (VLP) based-respiratory syncytial virus (RSV) vaccine to prevent the disease caused by this pathogen. The respiratory illnesses provokedby RSV in infants, children and the elderly are of global economical and public health impact. A recent worldwide estimate [5] indicates that ov ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government